Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

The company maintains its clinical asset timelines while redirecting resources toward its radiotherapy pipeline.

Rhea-AI Summary

Molecular Partners (MOLN) is deepening its focus on targeted radiotherapy and plans to reduce its workforce by up to approximately 44%. The proposed reduction covers no more than 55 positions, with employee consultation underway. Implementation is expected by Q2 2027, with cost reductions fully effective early in H2 2027.

Dosing continues in the fully recruited second dose level of the MP0712 Phase 1/2a study. No dose-limiting events occurred in dose level 1; adverse events reported to date were mild to moderate and transient. Initial safety data are due in December 2026, with efficacy data expected in 2027.

Cash and cash equivalents were CHF 57.5 million at September 30, 2026. The company expects funding to last into late 2027 under current operating assumptions and forecasts 2026 operating expenses of CHF 50–55 million at constant exchange rates. Other radiotherapy programs continue advancing.

14 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.CHF 57.5 million cash and cash equivalents at September 30, 2026 are expected to fund operations into late 2027.
• Minor pointMP0712 dose level 1 patients completed safety observation without dose-limiting events; reported adverse events were mild to moderate and transient.
• Minor pointMP0712 dose level 2 is fully recruited, with dosing ongoing at 105 MBq per dose.
• Minor point. Forward-looking: it has not happened yet and may not happen.MP0712 trial expansion has 8 sites open; all 9 planned sites are expected to open in 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.MP0712 initial safety data are scheduled for December 2026; efficacy data are expected in 2027.

9 minor points

• Minor pointRadiotherapy pipeline development is being prioritized, with previously announced clinical asset timelines maintained.
• Minor point. Forward-looking: it has not happened yet and may not happen.Cost reductions from organizational changes are expected to become fully effective early in H2 2027.
• Minor pointMP0714 early-access clinical program has begun through NuMeRI under South Africa’s compassionate-care framework.
• Minor point. Forward-looking: it has not happened yet and may not happen.MP0726, targeting MSLN, is advancing to first-in-human imaging in H2 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.MP0730, targeting CD70, was nominated; its first-in-human program is anticipated to start mid 2027.
• Minor pointMP0730 mouse data showed sustained tumor uptake relative to healthy tissues, including kidney, liver and blood.
• Minor pointMultispecific Radio-DARPins are in development to engage multiple tumor targets simultaneously.
• Minor point. Forward-looking: it has not happened yet and may not happen.Other DARPin platforms will be explored through strategic partnerships and platform-derived spin-out opportunities.
• Minor point. Forward-looking: it has not happened yet and may not happen.MP0533 Phase 1/2a dose escalation is completed, with results scheduled for presentation in December 2026.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.No more than 55 positions, potentially up to approximately 44% of the workforce, face proposed elimination; employee consultation is underway.
• Moderate point. Forward-looking: it has not happened yet and may not happen.2026 operating expenses are forecast at CHF 50–55 million at constant exchange rates, including approximately CHF 5 million in non-cash costs.
• Minor point. Forward-looking: it has not happened yet and may not happen.Restructuring charge, including employee termination costs, is expected to be estimated with full-year 2026 results in early 2027.

News Explained

The restructuring charge, including employee termination costs, is not yet estimable while the company assesses affected employees; it expects to provide an estimate with its full-year 2026 results in early 2027.

Key Figures

Cash and cash equivalents: CHF 57.5 million Operating expense forecast: CHF 50–55 million Potential workforce reduction: Up to 55 positions +4 more

Cash and cash equivalents

CHF 57.5 million

As of September 30, 2026

Operating expense forecast

CHF 50–55 million

Full-year 2026, at constant exchange rates

Potential workforce reduction

Up to 55 positions

Consultation process initiated

Dose level 2

105 MBq per dose

MP0712 Phase 1/2a study; dosing ongoing

Dose-limiting events

None observed

Dose level 1 at 75 MBq per dose

Initial safety data

December 2026

MP0712 study presentation timing

Efficacy data

2027

MP0712 study expected timing

Historical Context

1 past event · Latest: Aug 25

1 event

1. Aug 25

   Earnings report

   24h Move

   -0.5%

   H1 set operating expenses at CHF 45–55 million and cash funding into late 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dose-limiting events, ifrs, chelators, biodistribution profile

4 terms

dose-limiting events medical

"no dose-limiting events observed"

Dose-limiting events are specific adverse effects or toxicities observed during a clinical trial that are serious or frequent enough to prevent raising a drug’s dose further. They are used to identify the maximum tolerated dose and shape a drug’s safety profile, which affects trial design, development timelines, regulatory review and commercial potential—think of them as warning signs that set a practical “speed limit” for how hard a drug can be pushed.

ifrs financial

"share-based payments, IFRS pension accounting and depreciation"

International Financial Reporting Standards (IFRS) are a set of common accounting rules used by many companies worldwide to prepare financial statements, so numbers like revenue, profit and assets are measured in the same way across borders. For investors, IFRS matters because it makes it easier to compare the financial health and performance of different companies—like using the same ruler to measure different objects—reducing surprises and helping informed investment decisions.

chelators technical

"including 212Pb and 225Ac and corresponding chelators"

Chemical compounds that bind and form stable complexes with metal ions by coordinating to the metal’s electron pairs; in medical and regulatory contexts they are drugs or agents used to remove, sequester, or transport metal ions (for example in treatment of heavy-metal poisoning, to control iron overload, or as part of a pharmaceutical formulation). Chelators work by creating a ring-like bond structure around the metal, altering its chemical behavior and often enabling the metal to be excreted; different chelators vary in which metals they bind and in strength, and they can also remove essential metals (causing side effects) if not used selectively.

biodistribution profile medical

"first data outlining an attractive biodistribution profile"

A biodistribution profile describes where, how much, and for how long a drug, biologic, or delivery vehicle (for example a viral vector, nanoparticle, or antibody) travels and accumulates in different organs, tissues, and body fluids after administration. It is determined by measuring the agent’s concentrations or markers in specific tissues over time using methods such as imaging, tissue sampling, PCR, or mass spectrometry, and it highlights target versus off‑target localization, persistence, and routes of clearance. Distinction: biodistribution focuses on the spatial pattern of exposure across tissues rather than only plasma concentration over time (pharmacokinetics), so it is used alongside PK and toxicology data to assess safety, potential off‑target effects, and regulatory requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Dosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027
• Emerging clinical data from lead Radio-DARPin candidate MP0712 enables strategic focus on radiopharmaceuticals
• Streamlining of organization, in line with corporate focus, to advance Radio-DARPin programs
• Cash position of CHF 57.5 million (USD ~69 million) as of September 30, 2026, expected to fund operations into late 2027

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics, (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the third quarter of 2026, as well as a deepened focus on radiopharmaceuticals and streamlining of its resources.

"This third quarter marked a decisive step in Molecular Partners’ transformation into a dedicated radiopharmaceuticals company. Encouraged by the emerging Phase 1/2a data from MP0712, our DLL3 Radio-DARPin for SCLC, we believe now is the time to focus on targeted radiotherapy. With efficacy data expected in 2027, we will continue to execute our lead asset MP0712 and advance our clinical Radio-DARPin programs to deliver value to shareholders and meaningful benefit to cancer patients,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.

Focused Strategy & Shaping of Organization to Advance Radiotherapeutics:
Based on the emerging clinical profile of MP0712, Molecular Partners is deepening its strategic focus on radiotherapeutic medicines, with priority on executing on the Phase 1/2a study of its lead clinical candidate MP0712, and on advancing its growing pipeline of Radio-DARPin therapeutics, with the ambition to build a leading radiopharmaceuticals company.

Reflective of its corporate focus, the Company will streamline its capabilities and resources to support the successful development of its Radio-DARPin programs in the clinic. The Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 55 positions, representing a potential of up to ~44% of positions. In accordance with Swiss employment law, a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. Molecular Partners foresees the full implementation of these changes enacted by Q2 2027 and the reduction of costs to become fully effective early in H2 2027.

Molecular Partners maintains its previously announced timelines on its clinical assets.

Research & Development Highlights

MP0712 (DLL3-targeting Radio-DARPin Therapy, RDT)

MP0712, the Company’s lead Radio-DARPin candidate targeting the tumor-associated antigen delta-like ligand 3 (DLL3) and carrying the therapeutic alpha-emitting payload ²¹²Pb, is being co-developed with strategic partner Orano Med, a pioneer in the development of ²¹²Pb-based targeted alpha therapies, for the treatment of small cell lung cancer (SCLC) and other neuroendocrine cancers.

The U.S. multicenter Phase 1/2a study of MP0712 (NCT07278479) is well underway with dosing ongoing in the fully recruited dose level 2 (105 MBq per dose) and 8 sites open. All 9 planned sites are expected to open in 2026. All patients in dose level 1 (75 MBq per dose) passed the safety observation period, with no dose-limiting events observed. All adverse events reported to date were mild to moderate (grade 1–2) and transient, resolving in time for the next regular dosing cycle. Initial safety data will be presented at the IASLC / ASCO North America Conference on Lung Cancer (NACLC) in December 2026. Efficacy data are expected in 2027.

Next RDT Programs

Molecular Partners pursues an isotope-agnostic strategy for its pipeline of targeted alpha therapeutics. The versatility of DARPins allows interchangeability of alpha isotopes, including ²¹²Pb and ²²⁵Ac and corresponding chelators, enabling candidates to be tailored to a specific target and disease biology.

The Nuclear Medicine Research Infrastructure (NuMeRI) has initiated an early-access clinical program, under the legal framework for compassionate care in South Africa, to image and treat patients with MP0714, a DLL3-targeting Radio-DARPin labeled with ¹⁷⁷Lu and ²²⁵Ac, respectively.

The Company’s MSLN-targeting RDT program MP0726 is advancing to first-in-human imaging in H2 2026. In addition, Molecular Partners has nominated MP0730, targeting the tumor-associated antigen CD70, as the third asset for its growing RDT pipeline. At the Discovery on Target – Radioligand Therapies conference in October 2026, the Company presented first data outlining an attractive biodistribution profile of MP0730 in tumor-bearing mice, with strong and sustained tumor uptake relative to healthy tissues, including kidney, liver and blood. First-in-human program is anticipated to start mid 2027.

Molecular Partners is also developing next-generation multispecific Radio-DARPins designed to engage multiple tumor targets simultaneously, with the aim of improving precision and therapeutic efficacy for highly heterogenous cancers, as showcased at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in July 2026.

Immune Cell Engagers

As part of its strategic focus on radiopharmaceuticals, Molecular Partners will continue to explore the broad therapeutic potential of its DARPin platforms, including Switch-DARPins inside and outside of oncology, through strategic partnerships and platform-derived spin-out opportunities, representing potential upside beyond its focus on radiotherapeutics. Recent activities from these programs include:

• A trial-in-progress poster on MP0317, a FAP-localized CD40 agonist, presented by the Phase 2 investigators at the European Society for Medical Oncology (ESMO) Congress 2026.
• Presentation of new pre-clinical data on MP0632, a logic-gated T cell engager, at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2026.
• Presentation of results from the completed Phase 1/2a dose escalation of MP0533, a novel tetra-specific T cell engager designed for selective mutation-agnostic killing of AML cells, at the American Society of Hematology (ASH) Annual Meeting in December 2026.
  

Financial and Business Outlook

For the full year 2026, at constant exchange rates, the Company updates its forecast with total operating expenses of CHF 50-55 million expected, including approximately CHF 5 million of non-cash effective costs for share-based payments, IFRS pension accounting and depreciation.

The Company's cash and cash equivalents are CHF 57.5 million (USD ~69 million) as of September 30, 2026 and based on current operating assumptions, is expected to be sufficient to fund its operating expenses and capital expenditure requirements into late 2027.

The financial impact from the restructuring is not estimable at this time, as Molecular Partners is still assessing the specifics of affected employees. The Company expects to be able to provide an estimate of the expected restructuring charge, including employee termination costs, as part of the full year 2026 results in early 2027.

Financial Calendar

March 5, 2027	Full Year 2026 results
April 14, 2027	Annual General Meeting

The latest timing of the above events can be viewed on the investor section of the website.

About Molecular Partners AG 
Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeutics for cancer patients underserved by existing treatment modalities. Molecular Partners focuses on the development of targeted radiotherapeutics, leveraging the unique properties of DARPin miniproteins as isotope-agnostic vector. The Company’s lead medicine MP0712, targeting DLL3 and armed with ²¹²Pb, advances in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers. Molecular Partners has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn.

For further details, please contact:
Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Corporate Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; Molecular Partners' plans to streamline its organization and related workforce reductions, and its anticipated scope, cost, timing and benefits; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Molecular Partners report about MP0712 trial safety and upcoming data?

All MP0712 dose level 1 patients passed safety observation with no dose-limiting events, and all adverse events reported to date were mild to moderate and transient. Dosing continues in the fully recruited second dose level. Initial safety data are scheduled for December 2026, with efficacy data expected in 2027.

How many jobs does Molecular Partners plan to cut, and when?

Molecular Partners intends to eliminate no more than 55 positions, representing potentially up to approximately 44% of positions. Employee consultation has begun. The company expects full implementation by Q2 2027 and cost reductions to become fully effective early in H2 2027.

When will Molecular Partners estimate its restructuring charge?

Molecular Partners expects to provide an estimate of its restructuring charge, including employee termination costs, with full-year 2026 results in early 2027. The financial impact is not yet estimable because the specifics of affected employees remain under assessment.